Fosmidomycin decreases membrane hopanoids and potentiates the effects of colistin on burkholderia multivorans clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5211-5219

  Malott, Rebecca J ^a,f   Wu, Chia Hung ^b   Lee, Tracy D ^a   Hird, Trevor J ^a   Dalleska, Nathan F ^c   Zlosnik, James E A ^a   Newman, Dianne K ^b,d,e   Speert, David P ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b California Institute of Technology   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^f Sanofi Pasteur   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; FOSMIDOMYCIN; HOPANOID; LIPID; POLYMYXIN B; ANTIINFECTIVE AGENT; FOSFOMYCIN; PENTACYCLIC TRITERPENE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BINDING ASSAY; BURKHOLDERIA MULTIVORANS; CYSTIC FIBROSIS; HUMAN; LIQUID CHROMATOGRAPHY; LUNG INFECTION; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; PHYSICIAN; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; TANDEM MASS SPECTROMETRY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BURKHOLDERIA; CELL MEMBRANE; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BURKHOLDERIA; CELL MEMBRANE; COLISTIN; DRUG SYNERGISM; FOSFOMYCIN; MICROBIAL SENSITIVITY TESTS; PENTACYCLIC TRITERPENES;

EID: 84906084138     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02705-14     Document Type: Article

References (45)

1. Mahenthiralingam E, Baldwin A, Dowson CG. 2008. Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology. J. Appl. Microbiol. 104:1539-1551. http://dx.doi.org/10.1111/j.1365-2672.2007. 03706.x. (Pubitemid 351724983)
2. Drevinek P, Mahenthiralingam E. 2010. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin. Microbiol. Infect. 16:821-830. http://dx.doi.org/10.1111/j.1469-0691.2010.03237.x.
3. Isles A, Maclusky I, Corey M, Gold R, Prober C, Fleming P, Levison H. 1984. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J. Pediatr. 104:206-210. http://dx.doi.org/10.1016/S0022-3476(84)80993-2. (Pubitemid 14188925)
4. Mahenthiralingam E, Urban TA, Goldberg JB. 2005. The multifarious, multireplicon Burkholderia cepacia complex. Nat. Rev. Microbiol. 3:144-156. http://dx.doi.org/10.1038/nrmicro1085. (Pubitemid 40207595)
5. Loutet SA, Valvano MA. 2011. Extreme antimicrobial peptide and polymyxin B resistance in the genus Burkholderia. Front. Microbiol. 2:159. http://dx.doi.org/10.3389/fmicb.2011.00159.
6. Govan JR, Brown AR, Jones AM. 2007. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol. 2:153-164. http://dx.doi.org/10.2217/17460913.2.2. 153. (Pubitemid 46766989)
7. Bumford AA, Spilker T, LiPuma J. 2010. Epidemiology of Burkholderia infection in U.S. CF patients, abstr 1A, p 1. Abstracts of the International Burkholderia cepacia Working Group Meeting, 21 to 24 April 2010, Seattle, WA.
8. Zlosnik JE, Henry DA, Speert DP. 2011. Burkholderia cepacia complex infections in Vancouver and British Columbia from 1981 to 2010, abstr A1, p 1, Abstracts of the International Burkholderia cepacia Working Group Meeting, 14 to 16 April 2011, Prague, Czech Republic.
9. Whiteford ML, Wilkinson JD, McColl JH, Conlon FM, Michie JR, Evans TJ, Paton JY. 1995. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax 50:1194-1198. http://dx.doi.org/10.1136/thx.50.11.1194.
10. Segonds C, Heulin T, Marty N, Chabanon G. 1999. Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates. J. Clin. Microbiol. 37:2201-2208. (Pubitemid 29277780)
11. Beringer P. 2001. The clinical use of colistin in patients with cystic fibrosis. Curr. Opin. Pulm. Med. 7:434-440. http://dx.doi.org/10.1097/00063198- 200111000-00013. (Pubitemid 33065550)
12. Loutet SA, Mussen LE, Flannagan RS, Valvano MA. 2011. A two-tier model of polymyxin B resistance in Burkholderia cenocepacia. Environ. Microbiol. Rep. 3:278-285. http://dx.doi.org/10.1111/j.1758-2229.2010.00222.x.
13. Manniello JM, Heymann H, Adair FW. 1978. Resistance of spheroplasts and whole cells of Pseudomonas cepacia to polymyxin B. Antimicrob. Agents Chemother. 14:500-504. http://dx.doi.org/10.1128/AAC.14.3.500. (Pubitemid 9025678)
14. Moore RA, Chan L, Hancock RE. 1984. Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 26:539-545. http://dx.doi.org/10.1128/AAC.26.4.539. (Pubitemid 14018093)
15. Cox AD, Wilkinson SG. 1991. Ionizing groups in lipopolysaccharides of Pseudomonas cepacia in relation to antibiotic resistance. Mol. Microbiol. 5:641-646. http://dx.doi.org/10.1111/j.1365-2958.1991.tb00735.x. (Pubitemid 21896085)
16. Loutet SA, Flannagan RS, Kooi C, Sokol PA, Valvano MA. 2006. A complete lipopolysaccharide inner core oligosaccharide is required for resistance of Burkholderia cenocepacia to antimicrobial peptides and bacterial survival in vivo. J. Bacteriol. 188:2073-2080. http://dx.doi.org/10.1128/JB.188.6.2073-2080. 2006. (Pubitemid 43376461)
17. Ortega X, Silipo A, Saldias MS, Bates CC, Molinaro A, Valvano MA. 2009. Biosynthesis and structure of the Burkholderia cenocepacia K56-2 lipopolysaccharide core oligosaccharide: truncation of the core oligosaccharide leads to increased binding and sensitivity to polymyxin B. J. Biol. Chem. 284:21738-21751. http://dx.doi.org/10.1074/jbc.M109.008532.
18. Malott RJ, Steen-Kinnaird BR, Lee TD, Speert DP. 2012. Identification of hopanoid biosynthesis genes involved in polymyxin resistance in Burkholderia multivorans. Antimicrob. Agents Chemother. 56:464-471. http://dx.doi.org/10. 1128/AAC.00602-11.
19. Sass A, Marchbank A, Tullis E, Lipuma JJ, Mahenthiralingam E. 2011. Spontaneous and evolutionary changes in the antibiotic resistance of Burkholderia cenocepacia observed by global gene expression analysis. BMC Genomics 12:373. http://dx.doi.org/10.1186/1471-2164-12-373.
20. Schmerk CL, Bernards MA, Valvano MA. 2011. Hopanoid production is required for low-pH tolerance, antimicrobial resistance, and motility in Burkholderia cenocepacia. J. Bacteriol. 193:6712-6723. http://dx.doi.org/10. 1128/JB.05979-11.
21. Kannenberg EL, Poralla K. 1999. Hopanoid biosynthesis and function in bacteria. Naturwissenschaften 86: 168 -176. http://dx.doi.org/10.1007/ s001140050592.
22. Rezanka T, Siristova L, Melzoch K, Sigler K. 2010. Hopanoids in bacteria and cyanobacteria-their role in cellular biochemistry and physiology, analysis and occurrence. Mini Rev. Org. Chem. 7:300-313. http://dx.doi.org/10.2174/ 157019310792246436.
23. Cvejic JH, Putra SR, El-Beltagy A, Hattori R, Hattori T, Rohmer M. 2000. Bacterial triterpenoids ofthehopaneseries asbiomarkersforthechemotaxonomy of Burkholderia, Pseudomonas and Ralstonia spp. FEMS Microbiol. Lett. 183:295-299. http://dx.doi.org/10.1111/j.1574-6968.2000.tb08974.x. (Pubitemid 30079664)
24. Zhang B, Watts KM, Hodge D, Kemp LM, Hunstad DA, Hicks LM, Odom AR. 2011. A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling. Biochemistry 50:3570-3577. http://dx.doi.org/10.1021/bi200113y.
25. Rohmer M, Grosdemange-Billiard C, Seemann M, Tritsch D. 2004. Isoprenoid biosynthesis as a novel target for antibacterial and antiparasitic drugs. Curr. Opin. Investig. Drugs 5:154-162.
26. Messiaen AS, Verbrugghen T, Declerck C, Ortmann R, Schlitzer M, Nelis H, Van Calenbergh S, Coenye T. 2011. Resistance of the Burkholderia cepacia complex to fosmidomycin and fosmidomycin derivatives. Int. J. Antimicrob. Agents 38:261-264. http://dx.doi.org/10.1016/j.ijantimicag.2011.04.020.
27. Speert DP, Henry D, Vandamme P, Corey M, Mahenthiralingam E. 2002. Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg. Infect. Dis. 8:181-187. http://dx.doi.org/10.3201/eid0802.010163. (Pubitemid 34202443)
28. Mahenthiralingam E, Coenye T, Chung JW, Speert DP, Govan JR, Taylor P, Vandamme P. 2000. Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J. Clin. Microbiol. 38:910-913. (Pubitemid 30082711)
29. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard - ninth edition. M07-A9, vol 32. Clinical and Laboratory Standards Institute, Wayne, PA.
30. Yokota Y, Murakawa T, Nishida M. 1981. In vitro synergism of FR-31564, a new phosphonic acid antibiotic. J. Antibiot. 34:876-883. http://dx.doi.org/10. 7164/antibiotics.34.876. (Pubitemid 11005585)
31. Zlosnik JE, Costa PS, Brant R, Mori PY, Hird TJ, Fraenkel MC, Wilcox PG, Davidson AG, Speert DP. 2011. Mucoid and nonmucoid Burkholderia cepacia complex bacteria in cystic fibrosis infections. Am. J. Respir. Crit. Care Med. 183:67-72. http://dx.doi.org/10.1164/rccm.201002-0203OC.
32. Isaac G, McDonald S, Astarita G. 2011. Lipid separation using UPLC with charged surface hybrid technology. Waters Corporation, Milford, MA.
33. Burtnick MN, Woods DE. 1999. Isolation of polymyxin B-susceptible mutants of Burkholderia pseudomallei and molecular characterization of genetic loci involved in polymyxin B resistance. Antimicrob. Agents Chemother. 43:2648-2656. (Pubitemid 29519543)
34. McKeon SA, Nguyen DT, Viteri DF, Zlosnik JE, Sokol PA. 2011. Functional quorum sensing systems are maintained during chronic Burkholderia cepacia complex infections in patients with cystic fibrosis. J. Infect. Dis. 203:383-392. http://dx.doi.org/10.1093/infdis/jiq054.
35. Coutinho CP, de Carvalho CC, Madeira A, Pinto-de-Oliveira A, Sa-Correia I. 2011. Burkholderia cenocepacia phenotypic clonal variation during a 3.5-year colonization in the lungs of a cystic fibrosis patient. Infect. Immun. 79:2950-2960. http://dx.doi.org/10.1128/IAI.01366-10.
36. Jassem AN, Zlosnik JE, Henry DA, Hancock RE, Ernst RK, Speert DP. 2011. In vitro susceptibility of Burkholderia vietnamiensis to aminoglycosides. Antimicrob. Agents Chemother. 55:2256-2264. http://dx.doi.org/10.1128/AAC.01434- 10.
37. Mahenthiralingam E, Baldwin A, Vandamme P. 2002. Burkholderia cepacia complex infection in patients with cystic fibrosis. J. Med. Microbiol. 51:533-538. (Pubitemid 34747981)
38. Hancock RE, Speert DP. 2000. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Updat. 3:247-255. http://dx.doi.org/10.1054/drup.2000.0152.
39. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H. 2006. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J. Antimicrob. Chemother. 57:306-311. http://dx.doi.org/10.1093/jac/dki461. (Pubitemid 43160174)
40. Na-Bangchang K, Ruengweerayut R, Karbwang J, Chauemung A, Hutchinson D. 2007. Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria. Malar. J. 6:70. http://dx.doi.org/10.1186/1475-2875-6-70.
41. Sud M, Fahy E, Cotter D, Brown A, Dennis EA, Glass CK, Merrill AH, Jr, Murphy RC, Raetz CR, Russell DW, Subramaniam S. 2007. LMSD: LIPID MAPS structure database. Nucleic Acids Res. 35:D527-D532. http://dx.doi.org/10.1093/nar/ gkl838. (Pubitemid 46056264)
42. Talbot HM, Rohmer M, Farrimond P. 2007. Rapid structural elucidation of composite bacterial hopanoids by atmospheric pressure chemical ionisation liquid chromatography/ion trap mass spectrometry. Rapid Commun. Mass Spectrom. 21: 880-892. http://dx.doi.org/10.1002/rcm.2911. (Pubitemid 46426807)
43. Loh B, Grant C, Hancock RE. 1984. Use of the fluorescent probe 1-Nphenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 26:546-551. http://dx.doi.org/10.1128/AAC.26.4.546. (Pubitemid 14018094)
44. Benincasa M, Pacor S, Gennaro R, Scocchi M. 2009. Rapid and reliable detection of antimicrobial peptide penetration into gram-negative bacteria based on fluorescence quenching. Antimicrob. Agents Chemother. 53: 3501-3504. http://dx.doi.org/10.1128/AAC.01620-08.
45. Avgeri SG, Matthaiou DK, Dimopoulos G, Grammatikos AP, Falagas ME. 2009. Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. Int. J. Antimicrob. Agents 33:394-404. http://dx.doi.org/10.1016/j.ijantimicag.2008.09.010.